Chemours (NYSE:CC) reported quarterly sales of $1.34 billion which beat the analyst consensus estimate of $1.27 billion by 5.35 percent. This is a 15.05 percent decrease over sales of $1.57 billion the same period last year.
HC Wainwright & Co. Reiterates Buy on ImmunoPrecise Antibodies, Maintains $9 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ImmunoPrecise Antibodies (NASDAQ:IPA) with a Buy and maintains $9 price target.
